Under the agreement, ProMetic will receive $1.4m and the client will be provided with a biosimilar product.
PBL chief executive officer Steve Burton said the company’s technology allows it to custom design affinity products according to each client’s specific needs, providing them with high-performance manufacturing processes and lower cost biological products.
"Furthermore, the application of our novel purification technology enables biosimilar manufacturers to avoid existing intellectual property developed and used for production of the original products and to generate new intellectual property around the new process which provides them with a competitive advantage" added Burton.